CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Joel W NealNick PavlakisSang-We KimYasushi GotoSun Min LimGiannis S MountziosElena FountzilasAnastasia MochalovaDaniel C ChristophAlessandra BearzXavier QuantinRamon PalmeroVladan AnticElaine ChunTirupathi Rao EdubilliYa-Chen LinMahrukh HuseniMarcus BallingerVilma GraupnerDominic CurranPiet VervaetThomas Newsom-DavisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Atezolizumab plus cabozantinib after disease progression following anti-PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.
Keyphrases
- phase iii
- locally advanced
- squamous cell carcinoma
- small cell lung cancer
- open label
- clinical trial
- rectal cancer
- phase ii
- double blind
- placebo controlled
- dna damage
- radiation therapy
- metastatic renal cell carcinoma
- cell cycle
- advanced non small cell lung cancer
- chemotherapy induced
- epidermal growth factor receptor